Surmodics Total Assets 2006-2019 | SRDX

Surmodics total assets from 2006 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
Surmodics Annual Total Assets
(Millions of US $)
2018 $164
2017 $137
2016 $133
2015 $99
2014 $105
2013 $102
2012 $104
2011 $157
2010 $170
2009 $186
2008 $191
2007 $171
2006 $157
2005 $124
Surmodics Quarterly Total Assets
(Millions of US $)
Q3 2019 $150
Q2 2019 $151
Q1 2018 $151
Q4 2018 $164
Q3 2018 $160
Q2 2018 $163
Q1 2017 $135
Q4 2017 $137
Q3 2017 $132
Q2 2017 $131
Q1 2016 $129
Q4 2016 $133
Q3 2016 $127
Q2 2016 $122
Q1 2015 $112
Q4 2015 $99
Q3 2015 $96
Q2 2015 $91
Q1 2014 $87
Q4 2014 $105
Q3 2014 $101
Q2 2014 $96
Q1 2013 $95
Q4 2013 $102
Q3 2013 $104
Q2 2013 $108
Q1 2012 $108
Q4 2012 $104
Q3 2012 $158
Q2 2012 $154
Q1 2011 $152
Q4 2011 $157
Q3 2011 $173
Q2 2011 $172
Q1 2010 $172
Q4 2010 $170
Q3 2010 $191
Q2 2010 $191
Q1 2009 $191
Q4 2009 $186
Q3 2009 $182
Q2 2009 $182
Q1 2008 $180
Q4 2008 $191
Q3 2008 $195
Q2 2008 $185
Q1 2007 $174
Q4 2007 $171
Q3 2007 $165
Q2 2007 $138
Q1 2006 $152
Q4 2006 $157
Q3 2006 $144
Q2 2006 $136
Q1 2005 $131
Q4 2005 $124
Q3 2005 $118
Q2 2005 $109
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.569B $0.081B
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $144.122B 20.23
Abbott Laboratories (ABT) United States $141.639B 26.63
Stryker (SYK) United States $79.044B 27.33
Boston Scientific (BSX) United States $52.905B 25.66
Baxter (BAX) United States $44.730B 27.12
EssilorLuxottica Societe Anonyme (ESLOY) France $31.899B 0.00
Zimmer Biomet Holdings (ZBH) United States $27.527B 17.62
Coloplast (CLPBY) Denmark $24.516B 39.14
Lonza Group Ag (LZAGY) Switzerland $24.500B 0.00
Terumo (TRUMY) Japan $23.332B 26.83
Smith & Nephew SNATS (SNN) United Kingdom $20.451B 0.00
ResMed (RMD) United States $18.758B 35.74
Sunny Optical Technology (SNPTF) China $16.343B 0.00
Bio-Rad Laboratories (BIO) United States $9.664B 51.80
Insulet (PODD) United States $9.336B 553.21
Canopy Growth (CGC) Canada $7.103B 0.00
Perrigo (PRGO) Ireland $7.075B 13.03
Hill-Rom Holdings (HRC) United States $6.550B 19.53
Haemonetics (HAE) United States $6.367B 48.05
William Demant Holdings (WILYY) Denmark $5.988B 0.00
GN STORE NORD (GNNDY) Denmark $5.322B 27.49
Shandong Weigao Medical Polymer (SHWGF) China $4.296B 0.00
Aurora Cannabis (ACB) Canada $3.796B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.645B 0.00
Neogen (NEOG) United States $3.284B 54.96
NuVasive (NUVA) United States $3.263B 26.01
ICU Medical (ICUI) United States $3.151B 20.44
Quidel (QDEL) United States $2.356B 23.39
Hutchison China MediTech (HCM) Hong Kong, SAR China $2.303B 0.00
Agios Pharmaceuticals (AGIO) United States $1.869B 0.00
National Vision Holdings (EYE) United States $1.827B 39.44
Cardiovascular Systems (CSII) United States $1.586B 0.00
Aphria (APHA) $1.164B 0.00
VAREX IMAGING (VREX) United States $1.064B 24.53
AtriCure (ATRC) United States $0.978B 0.00
Phibro Animal Health (PAHC) United States $0.849B 13.81
Eagle Pharmaceuticals (EGRX) United States $0.823B 20.97
Omeros (OMER) United States $0.745B 0.00
NanoString Technologies (NSTG) United States $0.737B 0.00
PetIQ (PETQ) United States $0.722B 17.07
Lantheus Holdings (LNTH) United States $0.721B 18.96
Cerus (CERS) United States $0.623B 0.00
LeMaitre Vascular (LMAT) United States $0.622B 36.89
MacroGenics (MGNX) United States $0.553B 0.00
Quanterix (QTRX) United States $0.529B 0.00
TG Therapeutics (TGTX) United States $0.491B 0.00
OraSure Technologies (OSUR) United States $0.461B 21.34
Owens & Minor (OMI) United States $0.410B 12.28
Meridian Bioscience (VIVO) United States $0.377B 11.76
Zynex (ZYXI) United States $0.362B 38.41
Utah Medical Products (UTMD) United States $0.349B 25.56
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.312B 0.00
BioLife Solutions (BLFS) United States $0.304B 93.44
United Health Products (UEEC) United States $0.242B 0.00
Bovie Medical (APYX) United States $0.223B 0.00
Vapotherm (VAPO) United States $0.167B 0.00
Rockwell Medical (RMTI) United States $0.156B 0.00
Cytosorbents (CTSO) United States $0.137B 0.00
Female Health (VERU) United States $0.134B 0.00
Fonar (FONR) United States $0.127B 8.93
Chimerix (CMRX) United States $0.100B 0.00
Chembio Diagnostics (CEMI) United States $0.097B 0.00
United-Guardian (UG) United States $0.084B 19.84
Nephros (NEPH) United States $0.068B 0.00
MTech Acquisition (KERN) United States $0.061B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.055B 0.00
ImmuCell (ICCC) United States $0.037B 0.00
Surface Oncology (SURF) United States $0.033B 0.00
Trinity Biotech (TRIB) Ireland $0.023B 0.00
Senestech (SNES) United States $0.023B 0.00
GUARDION HEALTH (GHSI) United States $0.021B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.011B 0.00
Capricor Therapeutics (CAPR) United States $0.009B 0.00
Valeritas Holdings (VLRX) United States $0.007B 0.00
Akers Biosciences Inc (AKER) United States $0.005B 0.00
NeuroMetrix (NURO) United States $0.003B 0.00